Printed from https://ideas.repec.org/s/spr/pharme3.html
Content
June 2021, Volume 39, Issue 6
- 639-651 Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US
by Drishti Shah & Lindsay Allen & Wanhong Zheng & Suresh S. Madhavan & Wenhui Wei & Traci J. LeMasters & Usha Sambamoorthi - 653-665 The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
by Paul E. Greenberg & Andree-Anne Fournier & Tammy Sisitsky & Mark Simes & Richard Berman & Sarah H. Koenigsberg & Ronald C. Kessler - 667-680 The Excess Costs of Depression and the Influence of Sociodemographic and Socioeconomic Factors: Results from the German Health Interview and Examination Survey for Adults (DEGS)
by Hannah König & Alexander Rommel & Julia Thom & Christian Schmidt & Hans-Helmut König & Christian Brettschneider & Alexander Konnopka - 681-690 Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors
by Jackie Yim & Joanne Shaw & Rosalie Viney & Sheena Arora & Nicole Ezendam & Alison Pearce - 691-706 The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder
by Alix Arnaud & Ellison Suthoff & Rita M. Tavares & Xuan Zhang & Aditi J. Ravindranath - 707-720 Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
by Maryia Zhdanava & Jennifer Voelker & Dominic Pilon & Tom Cornwall & Laura Morrison & Maude Vermette-Laforme & Patrick Lefebvre & Abigail I. Nash & Kruti Joshi & Cheryl Neslusan - 721-730 Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare
by Kaying Kan & Joran Lokkerbol & Frederike Jörg & Ellen Visser & Robert A. Schoevers & Talitha L. Feenstra - 731-739 Postnatal Major Depressive Disorder in Australia: Inequalities and Costs of Healthcare to Individuals, Governments and Insurers
by Emily J. Callander & Jenny Gamble & Debra K. Creedy
May 2021, Volume 39, Issue 5
- 481-483 Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative?
by Fernando Antoñanzas - 485-502 Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review
by Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski - 503-519 Utility Decrements Associated with Adult Overweight and Obesity in Australia: A Systematic Review and Meta-Analysis
by Joseph Carrello & Alison Hayes & Anagha Killedar & Amy Huben & Louise A. Baur & Stavros Petrou & Thomas Lung - 521-535 Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension
by Jing Wu & Shitong Xie & Xiaoning He & Gang Chen & Gengliang Bai & Da Feng & Ming Hu & Jie Jiang & Xiaohui Wang & Hongyan Wu & Qunhong Wu & John E. Brazier - 537-548 Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
by Yong-Jin Kim & Mark Oremus & Helen H. Chen & Thomas McFarlane & Danielle Fearon & Susan Horton - 549-561 RETRACTED ARTICLE: The EQ-5D-5L Valuation Study in Egypt
by Sahar A. Al Shabasy & Maggie M. Abbassi & Aureliano Paolo Finch & Darrin Baines & Samar F. Farid - 563-577 Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland
by Nadine Schur & Kapil Gudala & Umakanth Vudumula & Sreelatha Vadapalle & Arjun Bhadhuri & Alain Casanova & Nicholas Adlard & Matthias Schwenkglenks - 579-587 Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness
by Manuel Neves & Fernanda Trigo & Bergantim Rui & Cristina João & Paulo Lúcio & Neves Mariana & João Mendes & Hugo Pedrosa & Catarina Geraldes - 589-600 Using a Modified Delphi Approach to Gain Consensus on Relevant Comparators in a Cost-Effectiveness Model: Application to Prostate Cancer Screening
by Edna Keeney & Howard Thom & Emma Turner & Richard M. Martin & Sabina Sanghera - 601-615 Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
by Christopher Kruse & Sabrina Kretschmer & Anna Lipinski & Malte Verheyen & David Mengel & Monika Balzer-Geldsetzer & Stefan Lorenzl & Carmen Richinger & Christian Schmotz & Lars Tönges & Dirk Woitalla & Stephan Klebe & Anette Schrag & Richard Dodel
April 2021, Volume 39, Issue 4
- 379-382 Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment
by R. Brett McQueen & Julia F. Slejko - 383-397 Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
by Simone A. Huygens & Matthijs M. Versteegh & Stefan Vegter & L. Jan Schouten & Tim A. Kanters - 399-420 Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review
by Anindit Chhibber & Alexandre Hikiji Watanabe & Chayutthaphong Chaisai & Sajesh K. Veettil & Nathorn Chaiyakunapruk - 421-432 The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States
by Anita J. Brogan & Sandra E. Talbird & Ashley E. Davis & Elizabeth M. La & Princy N. Kumar - 433-446 Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success
by Björn Schwander & Mark Nuijten & Silvia Evers & Mickaël Hiligsmann - 447-461 Macrovascular Risk Equations Based on the CANVAS Program
by Michael Willis & Christian Asseburg & April Slee & Andreas Nilsson & Cheryl Neslusan - 463-471 EQ-5D-Y Value Set for Slovenia
by Valentina Prevolnik Rupel & Marko Ogorevc - 473-475 Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
by Kelly Hollenack & Jade Marshall - 477-478 Authors’ Reply to Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome”
by Edward E. Neuberger & Josh J. Carlson & David L. Veenstra - 479-480 The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases
by Jesse Elliott & George A. Wells & Doug Coyle
March 2021, Volume 39, Issue 3
- 271-273 Productivity-Adjusted Life-Years: A New Metric for Quantifying Disease Burden
by Zanfina Ademi & Ilana N. Ackerman & Ella Zomer & Danny Liew - 275-285 Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment
by Seamus Kent & Edward Burn & Dalia Dawoud & Pall Jonsson & Jens Torup Østby & Nigel Hughes & Peter Rijnbeek & Jacoline C. Bouvy - 287-315 Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data
by Marina Treskova & Francisco Pozo-Martin & Stefan Scholz & Viktoria Schönfeld & Ole Wichmann & Thomas Harder - 317-330 Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
by Elizabeth Wehler & Dominik Lautsch & Stacey Kowal & Glenn Davies & Andrew Briggs & Qianyi Li & Swapnil Rajpathak & Adnan Alsumali - 331-343 Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
by Marwân-al-Qays Bousmah & Marie Libérée Nishimwe & Tamara Tovar-Sanchez & Martial Lantche Wandji & Mireille Mpoudi-Etame & Gwenaëlle Maradan & Pierrette Omgba Bassega & Marie Varloteaux & Alice Montoyo & Charles Kouanfack & Eric Delaporte & Sylvie Boyer - 345-356 What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma
by Sven L. Klijn & Elisabeth Fenwick & Sonja Kroep & Kasper Johannesen & Bill Malcolm & Murat Kurt & Christopher Kiff & John Borrill - 357-372 Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden
by Ronan Mahon & Andrea Lang & Pamela Vo & Jasper Huels & Philip Cooney & Andriy Danyliv & Umakanth Vudumula & Sreelatha Vadapalle & Farooq Maniyar & Peter J. Goadsby - 373-377 Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review
by Adam J. N. Raymakers & Kristina M. Jenei & Dean A. Regier & Michael M. Burgess & Stuart J. Peacock
February 2021, Volume 39, Issue 2
- 139-146 NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests
by James F. O’Mahony & Mike Paulden & Chris McCabe - 147-160 Modifying NICE’s Approach to Equity Weighting
by Mike Paulden & Christopher McCabe - 161-169 Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
by Pedram Sendi - 171-180 Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem J. A. Witlox & Sabine E. Grimm & Rob Riemsma & Nigel Armstrong & Steve Ryder & Steven Duffy & Vanesa Huertas Carrera & Pawel Posadzki & Gillian Worthy & Xavier G. L. V. Pouwels & Bram L. T. Ramaekers & Jos Kleijnen & Manuela A. Joore & Antoinette D. I. Asselt - 181-209 An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis
by Nannan Li & Dennis Cornelissen & Stuart Silverman & Daniel Pinto & Lei Si & Ingrid Kremer & Sandrine Bours & Robin de Bot & Annelies Boonen & Silvia Evers & Joop van den Bergh & Jean-Yves Reginster & Mickaël Hiligsmann - 211-229 Health State Utilities of Patients with Heart Failure: A Systematic Literature Review
by Gian Luca Di Tanna & Michael Urbich & Heidi S. Wirtz & Barbara Potrata & Marieke Heisen & Craig Bennison & John Brazier & Gary Globe - 231-241 The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
by Katrine Wallace & Kelly Adamski & Ashwini Pai & Darya Rose & Anita Chawla - 243-256 Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
by Luis Hernandez & Malinda O’Donnell & Maarten Postma - 257-269 Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs
by Baudouin Standaert & Christophe Sauboin & Quentin J. Leclerc & Mark P. Connolly
January 2021, Volume 39, Issue 1
- 1-17 The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
by Rick A. Vreman & Joost W. Geenen & Saskia Knies & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Wim G. Goettsch - 19-24 Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier
by Christopher McCabe & Giovanni Tramonti & Andrew Sutton & Peter Hall & Mike Paulden - 25-61 Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions
by Ruth A. Lewis & Dyfrig Hughes & Alex J. Sutton & Clare Wilkinson - 63-80 Health Economic Evaluation Alongside Stepped Wedge Trials: A Methodological Systematic Review
by Thomas Lung & Lei Si & Richard Hooper & Gian Luca Di Tanna - 81-97 Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review
by Akira Yuasa & Naohiro Yonemoto & Michael LoPresti & Shunya Ikeda - 99-108 The Relative Importance of Education and Criminal Justice Costs and Benefits in Economic Evaluations: A Best–Worst Scaling Experiment
by Irina Pokhilenko & Luca M. M. Janssen & Mickael Hiligsmann & Silvia M. A. A. Evers & Ruben M. W. A. Drost & Aggie T. G. Paulus & Leonarda G. M. Bremmers - 109-119 Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions
by Linda Yamoah & Nick Dragojlovic & Alesha Smith & Larry D. Lynd & Carlo A. Marra - 121-131 Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia
by Carla Mamolo & Verna Welch & Roland B. Walter & Joseph C. Cappelleri & James Brockbank & Matthew Cawson & Chris Knight & Michele Wilson - 133-135 Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
by Bram L. T. Ramaekers & Ben Wijnen & Nigel Armstrong & Svenja Petersohn & Talitha Feenstra & Junfeng Wang & Manuela A. Joore - 137-138 Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
by Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos
December 2020, Volume 38, Issue 12
- 1283-1288 The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
by David G. T. Whitehurst & John E. Brazier & Rosalie Viney & Brendan J. Mulhern - 1289-1295 Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?
by Luke B. Connelly & Stephen Birch - 1297-1308 Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
by Aris Angelis & Huseyin Naci & Allan Hackshaw - 1309-1318 Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal
by Caroline Farmer & Ash Bullement & David Packman & Linda Long & Sophie Robinson & Elham Nikram & Anthony J. Hatswell & G. J. Melendez-Torres & Louise Crathorne - 1319-1331 Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
by Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin - 1333-1343 Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
by Ching-Yu Wang & Phuong N. Pham & Thuy N. Thai & Joshua D. Brown - 1345-1358 Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
by Lei Tian & Xiaomo Xiong & Qiang Guo & Yixi Chen & Luying Wang & Peng Dong & Aixia Ma - 1359-1372 Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups
by Shweta Mital & Hai V. Nguyen - 1373-1374 Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
by Richard Manning - 1375-1376 Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
by William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson - 1377-1377 Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018
by David D. Kim & Madison C. Silver & Natalia Kunst & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann
November 2020, Volume 38, Issue 11
- 1149-1151 On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?
by Kamal Desai & Eric Druyts & Kevin Yan & Chakrapani Balijepalli - 1153-1164 Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers
by Risha Gidwani & Louise B. Russell - 1165-1185 Integrative Review of Managed Entry Agreements: Chances and Limitations
by Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & André Luiz Pereira & Marcus Carvalho Borin & Isabella Figueiredo Zuppo & Roberto Iunes & Tomas Pippo & Renata Curi Hauegen & Carlos Vassalo & Tracey-Lea Laba & Steven Simoens & Sergio Márquez & Carolina Gomez & Luka Voncina & Gisbert W. Selke & Livio Garattini & Hye-Young Kwon & Jolanta Gulbinovic & Aneta Lipinska & Maciej Pomorski & Lindsay McClure & Jurij Fürst & Rosana Gambogi & Carla Hernandez Ortiz & Vânia Cristina Canuto Santos & Denizar Vianna Araújo & Vânia Eloisa Araujo & Francisco de Assis Acurcio & Juliana Alvares-Teodoro & Augusto Afonso Guerra-Junior - 1187-1200 Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer
by Erik F. Blom & Kevin ten Haaf & Harry J. Koning - 1201-1218 A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
by Wei Gao & Dominic Muston & Matthew Monberg & Kimmie McLaurin & Robert Hettle & Elizabeth Szamreta & Elyse Swallow & Su Zhang & Iden Kalemaj & James Signorovitch & R. Brett McQueen - 1219-1236 A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)
by Michael Urbich & Gary Globe & Krystallia Pantiri & Marieke Heisen & Craig Bennison & Heidi S. Wirtz & Gian Luca Di Tanna - 1237-1245 Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome
by Edward E. Neuberger & Josh J. Carlson & David L. Veenstra - 1247-1261 Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering
by Mohamed El Alili & Johanna M. Dongen & Keith S. Goldfeld & Martijn W. Heymans & Maurits W. Tulder & Judith E. Bosmans - 1263-1275 Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data
by Koen Degeling & Hui-Li Wong & Hendrik Koffijberg & Azim Jalali & Jeremy Shapiro & Suzanne Kosmider & Rachel Wong & Belinda Lee & Matthew Burge & Jeanne Tie & Desmond Yip & Louise Nott & Adnan Khattak & Stephanie Lim & Susan Caird & Peter Gibbs & Maarten IJzerman - 1277-1277 Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers
by Risha Gidwani & Louise B. Russell
October 2020, Volume 38, Issue 10
- 1021-1029 Future of Data Analytics in the Era of the General Data Protection Regulation in Europe
by Katarzyna Kolasa & W. Ken Redekop & Alexander Berler & Vladimir Zah & Carl V. Asche - 1031-1042 Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
by Meenakshi Srinivasan & Annesha White & Ayyappa Chaturvedula & Valvanera Vozmediano & Stephan Schmidt & Leo Plouffe & La’Marcus T. Wingate - 1043-1053 Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Ben Wijnen & Nigel Armstrong & Bram Ramaekers & Willem Witlox & Marie Westwood & Debra Fayter & Steve Ryder & Titas Buksnys & Gill Worthy & Kate Misso & Sabine Grimm & Jos Kleijnen & Manuela Joore - 1055-1070 Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines
by Bogdan Grigore & Oriana Ciani & Florian Dams & Carlo Federici & Saskia Groot & Meilin Möllenkamp & Stefan Rabbe & Kosta Shatrov & Antal Zemplenyi & Rod S. Taylor - 1071-1094 Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies
by Gatien Broucker & So Yoon Sim & Logan Brenzel & Margaret Gross & Bryan Patenaude & Dagna O. Constenla - 1095-1113 Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
by Clara Marquina & Ella Zomer & Sandra Vargas-Torres & Sophia Zoungas & Richard Ofori-Asenso & Danny Liew & Zanfina Ademi - 1115-1121 Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
by William V. Padula & Sonal Parasrampuria & Mariana P. Socal & Rena M. Conti & Gerard F. Anderson - 1123-1133 External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions
by Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos - 1135-1145 Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
by David D. Kim & Madison C. Silver & Natalia Kunst & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann - 1147-1147 Correction to: Calculating and Interpreting ICERs and Net Benefit
by Mike Paulden
September 2020, Volume 38, Issue 9
- 901-903 Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review
by Paul Catchpole & Victoria Barrett - 905-911 Financing Drug Innovation in the US: Current Framework and Emerging Challenges
by David Cutler & Noam Kirson & Genia Long - 913-926 Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence?
by Luiza Raquel Grazziotin & Gillian Currie & Michelle M. A. Kip & Maarten J. IJzerman & Marinka Twilt & Raymond Lee & Deborah A. Marshall - 927-939 Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
by T. Joseph Mattingly & Bryan L. Love & Bilal Khokhar - 941-951 Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
by Sang Kyu Cho & Beenish S. Manzoor & Kavita R. Sail & Hélène Parisé & Arliene Ravelo & Sheila Shapouri & Tatyana Kapustyan & Simon Sharmokh & Suchin Virabhak & Matthew S. Davids & Scott Johnson - 953-969 Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM
by Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen - 971-980 Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis
by Jesse Elliott & Bláthnaid McCoy & Tammy Clifford & Beth K. Potter & George A. Wells & Doug Coyle - 981-994 Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
by Thomas O’Connell & Marric Buessing & Scott Johnson & Lufei Tu & Simu K. Thomas & Ioannis Tomazos - 995-1005 Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates
by Allison Portnoy & Kelsey Vaughan & Emma Clarke-Deelder & Christian Suharlim & Stephen C. Resch & Logan Brenzel & Nicolas A. Menzies - 1007-1020 Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
by Ning Kam & Kanila Perera & Ella Zomer & Danny Liew & Zanfina Ademi
August 2020, Volume 38, Issue 8
- 777-779 Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
by James F. O’Mahony - 781-784 Why it’s Time to Abandon the ICER
by Mike Paulden - 785-807 Calculating and Interpreting ICERs and Net Benefit
by Mike Paulden - 809-818 Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses
by Michelle Q. T. Kwok & Mistura A. Kareem & Michael J. Cash & Fiona Lafferty & Katy Tobin & James F. O’Mahony - 819-837 A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
by Lucy Cunnama & Gabriela B. Gomez & Mariana Siapka & Ben Herzel & Jeremy Hill & Angela Kairu & Carol Levin & Dickson Okello & Willyanne DeCormier Plosky & Inés Garcia Baena & Sedona Sweeney & Anna Vassall & Edina Sinanovic - 839-856 Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States
by Kristina Burström & Fitsum Sebsibe Teni & Ulf-G. Gerdtham & Reiner Leidl & Gert Helgesson & Ola Rolfson & Martin Henriksson - 857-869 Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model
by Jason Gordon & Oliver Darlington & Phil McEwan & Matthew Lumley & Amer Taie & Meagen Hicks & Claudie Charbonneau & Angela Blake & Neil Hawkins & Simon Goldenberg & Jonathan Otter & Mark Wilcox - 871-881 Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff
by Tracy A. Comans & Kim-Huong Nguyen & Julie Ratcliffe & Donna Rowen & Brendan Mulhern - 883-892 Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
by Nils-Henning Ness & Dirk Schriefer & Rocco Haase & Benjamin Ettle & Tjalf Ziemssen - 893-894 Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?”
by Wui-Jin Koh & Robert W. Carlson - 895-896 Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?”
by Audrey Tran & Vinay Prasad - 897-897 Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
by Nils-Henning Ness & Dirk Schriefer & Rocco Haase & Benjamin Ettle & Tjalf Ziemssen - 899-900 Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology
by Lucy Cunnama & Gabriela B. Gomez & Mariana Siapka & Ben Herzel & Jeremy Hill & Angela Kairu & Carol Levin & Dickson Okello & Willyanne DeCormier Plosky & Inés Garcia Baena & Sedona Sweeney & Anna Vassall & Edina Sinanovic
July 2020, Volume 38, Issue 7
- 653-663 International Valuation Protocol for the EQ-5D-Y-3L
by Juan M. Ramos-Goñi & Mark Oppe & Elly Stolk & Koonal Shah & Simone Kreimeier & Oliver Rivero-Arias & Nancy Devlin - 665-681 Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations
by Matthew Franklin & James Lomas & Gerry Richardson - 683-713 Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review
by Koen Degeling & Martin Vu & Hendrik Koffijberg & Hui-Li Wong & Miriam Koopman & Peter Gibbs & Maarten IJzerman - 715-728 Economic Costs of Myasthenia Gravis: A Systematic Review
by Erik Landfeldt & Oksana Pogoryelova & Thomas Sejersen & Niklas Zethraeus & Ari Breiner & Hanns Lochmüller - 729-731 Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?
by Audrey A. Tran & Vinay Prasad - 733-735 What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society?
by R. Brett McQueen - 737-745 The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating
by Aaron P. Mitchell & Pranammya Dey & Jennifer A. Ohn & Sara M. Tabatabai & Michael A. Curry & Peter B. Bach - 747-764 Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden
by Julia Widén & Magnus Ivarsson & Lovisa Schalin & Polina Vrouchou & Matthias Schwenkglenks & Olof Heimbürger & Zanfina Ademi & C. Simone Sutherland - 765-776 R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study
by Rose Hart & Darren Burns & Bram Ramaekers & Shijie Ren & Daniel Gladwell & Will Sullivan & Niall Davison & Owain Saunders & Indeg Sly & Theresa Cain & Dawn Lee
June 2020, Volume 38, Issue 6
- 527-536 Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Peter Auguste & Jill Colquitt & Martin Connock & Emma Loveman & Rachel Court & Olga Ciccarelli & Carl Counsell & Xavier Armoiry - 537-555 A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway
by Huajie Jin & Paul Tappenden & Stewart Robinson & Evanthia Achilla & James H. MacCabe & David Aceituno & Sarah Byford - 557-574 ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases
by Michela Meregaglia & Amanda Whittal & Elena Nicod & Michael Drummond - 575-591 A Comparison of the EQ-5D-3L and EQ-5D-5L
by Alexander James Thompson & Alex James Turner - 593-606 Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches
by Marco Boeri & Daniel Saure & Alexander Schacht & Elisabeth Riedl & Brett Hauber - 607-618 A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome
by Kelly Fust & Michael Maschio & Michele Kohli & Simron Singh & D. Mark Pritchard & Florence Marteau & Peter Myrenfors & Marion Feuilly - 619-631 Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa
by Sedona Sweeney & Anna Vassall & Lorna Guinness & Mariana Siapka & Natsayi Chimbindi & Don Mudzengi & Gabriela B. Gomez - 633-643 Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving
by Petra Baji & Miklós Farkas & Dominik Golicki & Valentina Prevolnik Rupel & Renske Hoefman & Werner B. F. Brouwer & Job Exel & Zsombor Zrubka & László Gulácsi & Márta Péntek - 645-648 Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’
by Ian Jacob & Karin Butler & Karolina Badora & Vanessa Gross & Annette Beiderbeck & Steve Morris & Phil McEwan - 649-651 Response to Comment on “Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
by Xavier G. L. V. Pouwels & Svenja Petersohn & Vanesa Huertas Carrera & Alastair K. Denniston & Annette Chalker & Heike Raatz & Nigel Armstrong & Willem Witlox & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Manuela A. Joore
May 2020, Volume 38, Issue 5
- 427-429 We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can
by Elliot B. Tapper & Jagpreet Chhatwal - 431-441 Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier G. L. V. Pouwels & Svenja Petersohn & Vanesa Huertas Carrera & Alastair K. Denniston & Annette Chalker & Heike Raatz & Nigel Armstrong & Dhwani Shah & Willem Witlox & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Manuela A. Joore - 443-458 Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity
by Adriënne H. Rotteveel & Mattijs S. Lambooij & Nicolaas P. A. Zuithoff & Job Exel & Karel G. M. Moons & G. Ardine Wit - 459-471 Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs
by Salah Ghabri & Laurent Lam & François Bocquet & Hans-Martin Spath - 473-484 Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review
by Matteo Ruggeri & Carlo Drago & Francesco Rosiello & Valentina Orlando & Costanza Santori - 485-497 Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements
by Pierre Johansen & Daniel Howard & Ryan Bishop & Søren Ilsøe Moreno & Kristine Buchholtz - 499-513 Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling
by Kim Dalziel & Max Catchpool & Borja García-Lorenzo & Inigo Gorostiza & Richard Norman & Oliver Rivero-Arias - 515-526 Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach
by Lih-Wen Mau & Jaime M. Preussler & Linda J. Burns & Susan Leppke & Navneet S. Majhail & Christa L. Meyer & Tatenda Mupfudze & Wael Saber & Patricia Steinert & David J. Vanness
April 2020, Volume 38, Issue 4
- 317-324 Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem J. A. Witlox & Antoinette D. I. Asselt & Robert Wolff & Nigel Armstrong & Gill Worthy & Annette Chalker & Titas Buksnys & Lisa Stirk & Jos Kleijnen & Manuela A. Joore & Sabine E. Grimm - 325-340 Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going?
by Donna Rowen & Oliver Rivero-Arias & Nancy Devlin & Julie Ratcliffe - 341-356 Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
by Wilfried Guets & Hareth Al-Janabi & Lionel Perrier - 357-373 Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis
by Stavros Petrou & Natnaree Krabuanrat & Kamran Khan - 375-384 Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-Score
by Anagha Killedar & Thomas Lung & Stavros Petrou & Armando Teixeira-Pinto & Alison Hayes - 385-395 A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity
by Tim S. Grant & Darren Burns & Christopher Kiff & Dawn Lee - 397-411 Determinants of Orphan Drug Prices in Germany
by Franziska Worm & Charalabos-Markos Dintsios - 413-425 A French Value Set for the EQ-5D-5L
by Luiz Flavio Andrade & Kristina Ludwig & Juan Manuel Ramos Goni & Mark Oppe & Gérard Pouvourville
March 2020, Volume 38, Issue 3
- 243-245 Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review
by Meindert Boysen & Ian Watson - 247-257 After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
by Mark Sculpher & Stephen Palmer - 259-267 Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study
by Elisabet Jacobsen & Dwayne Boyers & Alison Avenell - 269-283 Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review
by Alexander Moreno-Calderón & Thai S. Tong & Praveen Thokala - 285-296 Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio
by Fernando Alarid-Escudero & Karen M. Kuntz - 297-306 Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan
by Haruhisa Fukuda & Yoshihiko Yano & Daisuke Sato & Sachiko Ohde & Shinichi Noto & Ryo Watanabe & Osamu Takahashi - 307-313 Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
by Michael Ryan & Bonnie M. K. Donato & William Irish & Christoph Gasteyger & Gilbert L’Italien & Jeffrey Laurence - 315-315 Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
by Laura Panattoni & Paul M. Brown & Braden Te Ao & Mark Webster & Patrick Gladding
February 2020, Volume 38, Issue 2
- 125-134 Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices
by Brendan Shaw & Jorge Mestre-Ferrandiz - 135-141 One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
by Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall - 143-158 A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders
by Patrick Fahr & James Buchanan & Sarah Wordsworth - 159-170 Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review
by Xinyu Qian & Rachel Lee-Yin Tan & Ling-Hsiang Chuang & Nan Luo - 171-179 Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment
by David D. Kim & Gregory F. Guzauskas & Caroline S. Bennette & Anirban Basu & David L. Veenstra & Scott D. Ramsey & Josh J. Carlson - 181-192 Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada
by Feng Tian & Sherilyn K. D. Houle & Mhd. Wasem Alsabbagh & William W. L. Wong - 193-204 How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
by Ben Kearns & John Stevens & Shijie Ren & Alan Brennan - 205-216 Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
by Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Saskia Knies & Janneke Grutters & Manuela A. Joore - 217-231 Transferability of Economic Evaluations of Treatments for Advanced Melanoma
by Claire Gorry & Laura McCullagh & Michael Barry - 233-242 Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
by T. Joseph Mattingly & Julia F. Slejko & Eberechukwu Onukwugha & Eleanor M. Perfetto & Shyamasundaran Kottilil & C. Daniel Mullins
January 2020, Volume 38, Issue 1
- 1-4 The New and Non-Transparent Cancer Drugs Fund
by Eifiona M. Wood & Dyfrig A. Hughes - 5-24 Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians
by Alisa Likhitsup & Neehar D. Parikh - 25-37 Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis
by Alexander Konnopka & Hannah König - 39-56 A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
by Elizabeth Wehler & Natalie Boytsov & Claudia Nicolay & Oscar Herrera-Restrepo & Stacey Kowal - 57-68 Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study
by Dean A. Regier & David L. Veenstra & Anirban Basu & Josh J. Carlson - 69-84 Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
by Luis Hernandez & Hiroyo Kuwabara & Anshul Shah & Kaoru Yamabe & Heather Burnett & Kyle Fahrbach & Maria Koufopoulou & Ryuichi Iwakiri - 85-95 Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity
by Susanne Schmitz & Tatjana T. Makovski & Roisin Adams & Marjan Akker & Saverio Stranges & Maurice P. Zeegers - 97-108 Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes
by Caitlin Smare & Khalid Lakhdari & Justin Doan & John Posnett & Sukhvinder Johal - 109-119 The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation
by Margrét V. Bjarnadóttir & David R. Anderson & Kislaya Prasad & Ritu Agarwal & D. Alan Nelson - 121-122 Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’
by Livio Garattini & Nicholas Freemantle - 123-123 Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
by Elizabeth Wehler & Natalie Boytsov & Claudia Nicolay & Oscar Herrera-Restrepo & Stacey Kowal
December 2019, Volume 37, Issue 12
- 1417-1419 Could or Should We Use MCDA in the French HTA Process?
by Salah Ghabri & Jean-Michel Josselin & Benoît Maux - 1421-1449 Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review
by Shuangshuang Fu & Chi-Fang Wu & Michael Wang & David R. Lairson - 1451-1468 Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
by Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen - 1469-1483 The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
by Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas - 1485-1494 Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort
by Michael Laxy & Verena Maria Schöning & Christoph Kurz & Rolf Holle & Annette Peters & Christa Meisinger & Wolfgang Rathmann & Kristin Mühlenbruch & Katharina Kähm - 1495-1507 Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data
by Ya-Chen Tina Shih & Ying Xu & Chun-Ru Chien & Bumyang Kim & Yu Shen & Liang Li & Daniel M. Geynisman - 1509-1523 Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease
by Heather Catt & Keith Bodger & Jamie J. Kirkham & Dyfrig A. Hughes - 1525-1536 A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis
by Sandjar Djalalov & Jaclyn Beca & Emmanuel M. Ewara & Jeffrey S. Hoch - 1537-1551 Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
by Venediktos Kapetanakis & Thibaud Prawitz & Michael Schlichting & K. Jack Ishak & Hemant Phatak & Mairead Kearney & John W. Stevens & Agnes Benedict & Murtuza Bharmal - 1553-1553 Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
by Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi
November 2019, Volume 37, Issue 11
- 1303-1304 Improving Transparency in Decision Models: Current Issues and Potential Solutions
by Paul Tappenden & J. Jaime Caro - 1305-1312 The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
by Seamus Kent & Frauke Becker & Talitha Feenstra & An Tran-Duy & Iryna Schlackow & Michelle Tew & Ping Zhang & Wen Ye & Shi Lizheng & William Herman & Phil McEwan & Wendelin Schramm & Alastair Gray & Jose Leal & Mark Lamotte & Michael Willis & Andrew J Palmer & Philip Clarke - 1313-1320 Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project
by Jeroen P. Jansen & Devin Incerti & Mark T. Linthicum - 1321-1327 Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
by Josh J. Carlson & Surrey M. Walton & Anirban Basu & Richard H. Chapman & Jonathan D. Campbell & R. Brett McQueen & Steven D. Pearson & Daniel R. Touchette & David Veenstra & Melanie D. Whittington & Daniel A. Ollendorf - 1329-1339 A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
by Fernando Alarid-Escudero & Eline M. Krijkamp & Petros Pechlivanoglou & Hawre Jalal & Szu-Yu Zoe Kao & Alan Yang & Eva A. Enns - 1341-1347 Cooking Up a Transparent Model Following a DICE Recipe
by Jörgen Möller - 1349-1354 Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
by Eric Q. Wu & Zheng-Yi Zhou & Jipan Xie & Cinzia Metallo & Praveen Thokala - 1355-1369 Transparency in Decision Modelling: What, Why, Who and How?
by Christopher James Sampson & Renée Arnold & Stirling Bryan & Philip Clarke & Sean Ekins & Anthony Hatswell & Neil Hawkins & Sue Langham & Deborah Marshall & Mohsen Sadatsafavi & Will Sullivan & Edward C. F. Wilson & Tim Wrightson - 1371-1381 Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics
by Emma McManus & David Turner & Tracey Sach - 1383-1390 NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence
by Ash Bullement & Matthew Taylor & Sam Thomas McMordie & Errol Waters & Anthony James Hatswell - 1391-1408 TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
by Nasuh C. Büyükkaramikli & Maureen P. M. H. Rutten-van Mölken & Johan L. Severens & Maiwenn Al - 1409-1410 Publication of Decision Model Source Code: Attitudes of Health Economics Authors
by Joanna Emerson & Rachel Bacon & Alma Kent & Peter J. Neumann & Joshua T. Cohen - 1411-1411 Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors
by Joanna Emerson & Rachel Bacon & Alma Kent & Peter J. Neumann & Joshua T. Cohen
October 2019, Volume 37, Issue 10
- 1195-1207 Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Sabine E. Grimm & Debra Fayter & Bram L. T. Ramaekers & Svenja Petersohn & Rob Riemsma & Nigel Armstrong & Xavier Pouwels & Willem Witlox & Caro Noake & Gillian Worthy & Jos Kleijnen & Manuela A. Joore - 1209-1217 Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Matthew Walton & Sahar Sharif & Mark Simmonds & Lindsay Claxton & Robert Hodgson